9 news items
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
, leading to ‘uncapping' of the chromosome ends and thus resulting in rapid tumor cell death
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
MAIA
7 Jun 24
of cancer-related deaths in the U.S., accounting for approximately 20% of all cancer fatalities. The American Cancer Society's
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
damage in cancer cells, triggering immune responses that lead to selective cancer cell death. This innovative mechanism not only disrupts the fundamental
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA
6 Jun 24
'-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
MAIA
4 Jun 24
-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic
ao7b0r2q7cg
AFMD
ALBT
BPTH
4 Jun 24
and selective cancer cell death. Accumulation of THIO-damaged telomeric fragments in cytosolic micronuclei activates both innate (cGAS/STING
zsbvpr15vfa480tt92jkdcmrvuukl0nec5qgay
CRL
IQV
MAIA
31 May 24
designed to selectively induce cancer cell death. THIO's unique mechanism of action involves targeting the telomerase enzyme, which is often upregulated
6k0wae6k83a
MAIA
22 May 24
by the Dana-Farber Cancer Institute explains that cancer cells often avoid senescence or cell death
0j3atzu whcsvsgwjdwl
MAIA
17 May 24
telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate
- Prev
- 1
- Next